Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma

2004 Background: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between Procarbazine, CCNU, and Vincristine (PCV) and Temozolomide (TMZ) remains unclear...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2024-06, Vol.42 (16_suppl), p.2004-2004
Hauptverfasser:	Kacimi, Salah Eddine O., Dehais, Caroline, Feuvret, Loïc, Chinot, Olivier L., Carpentier, Catherine, Bronnimann, Charlotte, Vauleon, Elodie, Djelad, Apolline, Cohen-Jonathan Moyal, Elizabeth L., Langlois, Olivier, Campone, Mario, Ducloie, Mathilde, Noel, Georges, Cuzzubbo, Stefania, Ricard, Damien, Faillot, Thierry, Boelle, Pierre-Yves, Figarella-Branger, Dominique, Ducray, Francois, Touat, Mehdi
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Life Sciences
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!